表紙
市場調查報告書
商品編碼
1084472

Rivaroxaban的全球市場:規模,佔有率,趨勢,預測(2022年∼2028年)

Rivaroxaban Market - Size, Share, Trends, and Forecast, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球Rivaroxaban的市場規模,由於適應症擴大的臨床試驗增加等所促進。同時,藥物的副作用和有替代療法可能抑制在預測期間內的該市場的成長。

本報告提供全球Rivaroxaban市場調查,市場概要,市場規模和預測,趨勢,成長要素,阻礙因素,各產品類型、用途、地區的分析,及競爭情形等資訊。

目錄

第1章 調查目的、前提條件

  • 調查目的
  • 假設
  • 簡稱

第2章 市場概要

  • 報告的說明
  • 市場定義和範圍
  • 摘要整理
    • 市場明細:各產品類型
    • 市場明細:各用途
    • 市場明細:各流通管道
    • 市場明細:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 產業趨勢
  • 法規情境
  • 流行病學

第4章 全球Rivaroxaban市場:各產品類型(2017年∼2028年)

  • 簡介
  • 10mg
  • 15mg
  • 20mg

第5章 全球Rivaroxaban市場:各用途(2017年∼2028年)

  • 簡介
  • 深部靜脈血栓症的預防
  • 肺動脈栓塞

第6章 全球Rivaroxaban市場:各流通管道(2017年∼2028年)

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 全球Rivaroxaban市場:各地區(2017年∼2028年)

  • 簡介
  • 北美
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 中國
  • 日本
  • 印度
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他南美國家
  • 中東
  • GCC各國
  • 以色列
  • 其他中東
  • 非洲
  • 北非
  • 中非
  • 南非

第8章 競爭情形

  • 熱圖分析
  • 企業簡介
    • Janssen Pharmaceuticals Inc.*
    • Bayer AG
  • 分析師的見解

第9章 Section

目錄
Product Code: CMI1962

Rivaroxaban is an anti-coagulant medication marketed under the brand name Xarelto by Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson. The report segments the rivaroxaban market based on strength of the drug, application, distribution channel, and region. The product is segmented into 10 mg, 15 mg, and 20 mg on the basis of strength and by application, it is segmented into deep venous thrombosis and pulmonary embolism. The report on rivaroxaban is intended to target the innovators and developers to provide in-depth analysis of the present market and the expected market scenario after the patent expiration. This report compiles the global rivaroxaban market overview, dynamics, opportunities, regional analysis, and market players.

Market Dynamics

Increasing clinical trials for the expansion of present indication of rivaroxaban is expected to be the key factor driving the rivaroxaban market growth over the forecast period. For instance, as per the data of clinical trials accessed on July 2018, Swiss Paraplegic Centre was evaluating rivaroxaban for cervical spinal cord injuries, with its successful entry in phase IV. The high cost of patented drug is a major factor contributing to high revenues and compound annual growth rate (CAGR). However, patent expiration of the drug in 2021 is expected to decrease the company revenues with the entry of new entrants with generic version of the drug at lower cost. The adverse effects of the drug such as risk of bleeding in patients leading to serious and fatal conditions are expected to restrain rivaroxaban market growth. Moreover, alternative therapies such as warfarin and heparin are cheaper, as compared to rivaroxaban and are expected to hamper growth of the global rivaroxaban market.

Key features of the study:

This report provides in-depth analysis of the rivaroxaban market and provides market size (US$ Million) and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global rivaroxaban market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans

Key companies covered as a part of this study include Janssen Pharmaceuticals Inc. and Bayer AG

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion, and marketing tactics

The global rivaroxaban market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of rivaroxaban, research and consulting firms, new entrants, and financial analysts

Various strategy matrices used in analyzing the rivaroxaban market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

Global Rivaroxaban Market, By Strength:

10 mg

15 mg

20 mg

Global Rivaroxaban Market, By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

Global Rivaroxaban Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Rivaroxaban Market, By Region:

By Strength:

10 mg

15 mg

20 mg

By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Country:

U.S.

Canada

Latin America

By Strength:

10 mg

15 mg

20 mg

By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By country:

Brazil

Mexico

Argentina

Rest of Latin America

Europe

By Strength:

10 mg

15 mg

20 mg

By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By country:

Germany

U.K.

Italy

France

Spain

Russia

Rest of Europe

Asia Pacific

By Strength:

10 mg

15 mg

20 mg

By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By country:

China

India

Japan

ASEAN

Australia

South Korea

Rest of Asia Pacific

Middle East

By Strength:

10 mg

15 mg

20 mg

By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By country:

GCC

Israel

Rest of Middle East

Africa

By Strength:

10 mg

15 mg

20 mg

By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By country:

North Africa

Central Africa

South Africa

Company Profiles

Janssen Pharmaceuticals Inc.*

Company Overview

Product Portfolio

Key Highlights

Financial Overview

Market Strategies

Bayer AG

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
  • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Strength
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Industry Trends
  • Regulatory Scenario
  • Epidemiology

4. Global Rivaroxaban Market, By Product Type, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • 10 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • 15 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • 20 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Rivaroxaban Market, By Application, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Deep Vein Thrombosis Prophylaxis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Pulmonary Embolism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Rivaroxaban Market, By Distribution Channel, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospitals Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Rivaroxaban Market, By Regions, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Strength, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
  • U.S.
  • Canada
  • Europe
    • Market Size and Forecast, By Strength, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Strength, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Strength, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Market Size and Forecast, By Strength, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Strength, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
  • Northern Africa
  • Central Africa
  • South Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Janssen Pharmaceuticals Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategies
    • Bayer AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact